Nordicus Partners Corporation reports developments as a business accelerator and holding company focused on Nordic and U.S. life sciences companies seeking access to the U.S. market. News about NORD centers on subsidiary formation and ownership, corporate finance activity, board governance, and updates from preclinical therapeutic programs.
The company’s recurring operating updates include Orocidin A/S and its QR-01 peptide candidate for periodontitis, Bio-Convert A/S and its QR-02 mucoadhesive oral topical formulation for oral leukoplakia, and majority-owned NoviThera ApS and its monoclonal antibody work for psoriasis. Coverage also includes manufacturing-process development, animal efficacy study activity, regulatory communications, and capital-structure disclosures.
Summary not available.
Summary not available.